We're sunsetting PodQuest on 2025-07-28. Thank you for your support!
Export Podcast Subscriptions
cover of episode Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI - Ep. 230

Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI - Ep. 230

2024/8/7
logo of podcast The AI Podcast

The AI Podcast

AI Deep Dive AI Chapters Transcript
People
C
Chris Gibson
Topics
Chris Gibson: 药物研发效率低下,失败率高达90%,生物学的复杂性是主要原因。Recursion公司致力于利用自动化、AI和大型数据集来加速药物研发,采用了一种工业化的方法。通过构建涵盖广泛生物学领域的巨型数据集,并利用AI进行分析预测,而非传统的针对单一疾病的研究方法。利用CRISPR-Cas9技术和自动化实验室,构建多层组学数据(基因组学、表型组学等),如同构建生物学的“谷歌地图”。传统的还原论方法在药物研发中存在局限性,而拥抱生物学的复杂性,并利用机器学习技术,可以发现意想不到的药物作用机制。早期利用机器学习技术探索生物学,尽管技术还不完善,但已展现出其潜力。Recursion公司利用“湿实验室”(实验)和“干实验室”(计算)的良性循环迭代方法,通过AI预测和实验验证不断改进模型,加速药物研发。某些生物领域(如遗传病、某些癌症和传染病)更容易研究,而神经科学领域则更具挑战性。Recursion公司构建了BioHive 2超级计算机,用于处理海量生物数据,并提升AI模型的性能。 Recursion公司开发了名为Lowe的工具,利用大型语言模型(LLM)和生成式AI,简化药物研发流程,并降低了对专业知识的要求。未来,在药物研发领域,对专业知识的理解和整合能力将比编程技能更重要,自然语言提示将成为主流。Recursion公司将继续开发药物,并将其推向临床试验,因为他们相信其技术能够显著提高药物研发的效率和成功率。Recursion公司独特的企业文化是其核心竞争力。 Noah Kravitz: 引导话题,提出问题,并对Chris Gibson的回答进行总结和回应。

Deep Dive

Chapters
Chris Gibson explains the mission of Recursion, which is to solve the problem of high drug failure rates in clinical trials by using new technologies to take a less biased approach to biology.

Shownotes Transcript

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Recursion, about how the company uses AI and machine learning to accelerate drug discovery and development at scale. Tune in to hear Gibson discuss how AI is transforming the biopharmaceutical industry by increasing efficiency and lowering discovery costs.